IL6 and diffuse large B-cell lymphoma: In sum, the Tandab(IL-6/CD20) protein could target CD20-positive DLBCL cells, as well as inhibit IL-6-related signaling pathway and eliminate the promoting effect of IL-6 on lymphoma cells.